BR112017023269A2 - métodos para tratamento de câncer - Google Patents
métodos para tratamento de câncerInfo
- Publication number
- BR112017023269A2 BR112017023269A2 BR112017023269A BR112017023269A BR112017023269A2 BR 112017023269 A2 BR112017023269 A2 BR 112017023269A2 BR 112017023269 A BR112017023269 A BR 112017023269A BR 112017023269 A BR112017023269 A BR 112017023269A BR 112017023269 A2 BR112017023269 A2 BR 112017023269A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- cancer treatment
- subject
- palbocyclib
- rad1901
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562154699P | 2015-04-29 | 2015-04-29 | |
US201562155451P | 2015-04-30 | 2015-04-30 | |
US201562158469P | 2015-05-07 | 2015-05-07 | |
US201562192944P | 2015-07-15 | 2015-07-15 | |
US201562192940P | 2015-07-15 | 2015-07-15 | |
US201562252085P | 2015-11-06 | 2015-11-06 | |
US201562252916P | 2015-11-09 | 2015-11-09 | |
US201562265696P | 2015-12-10 | 2015-12-10 | |
US201562265663P | 2015-12-10 | 2015-12-10 | |
US201562265774P | 2015-12-10 | 2015-12-10 | |
US201562265658P | 2015-12-10 | 2015-12-10 | |
US201662323572P | 2016-04-15 | 2016-04-15 | |
US201662323576P | 2016-04-15 | 2016-04-15 | |
PCT/US2016/030321 WO2016176666A1 (fr) | 2015-04-29 | 2016-04-29 | Méthodes de traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017023269A2 true BR112017023269A2 (pt) | 2018-11-06 |
Family
ID=57198783
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017023233A BR112017023233A2 (pt) | 2015-04-29 | 2016-04-29 | métodos para tratamento de câncer |
BR112017023269A BR112017023269A2 (pt) | 2015-04-29 | 2016-04-29 | métodos para tratamento de câncer |
BR112017023228A BR112017023228A2 (pt) | 2015-04-29 | 2016-04-29 | métodos para tratamento de câncer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017023233A BR112017023233A2 (pt) | 2015-04-29 | 2016-04-29 | métodos para tratamento de câncer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017023228A BR112017023228A2 (pt) | 2015-04-29 | 2016-04-29 | métodos para tratamento de câncer |
Country Status (14)
Country | Link |
---|---|
US (10) | US20180214393A1 (fr) |
EP (4) | EP4039253A1 (fr) |
JP (7) | JP6926065B2 (fr) |
KR (3) | KR20180043202A (fr) |
CN (5) | CN113750091A (fr) |
AU (3) | AU2016256470B2 (fr) |
BR (3) | BR112017023233A2 (fr) |
CA (3) | CA2984357A1 (fr) |
HK (3) | HK1251408A1 (fr) |
IL (7) | IL255261B2 (fr) |
MX (6) | MX2017013794A (fr) |
RU (3) | RU2747228C2 (fr) |
SG (4) | SG10202104177VA (fr) |
WO (3) | WO2016176665A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
DK3122426T3 (da) | 2014-03-28 | 2023-04-03 | Univ Duke | Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer |
EP4039253A1 (fr) * | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Procédés de traitement du cancer |
EP3416962B1 (fr) | 2016-02-15 | 2021-05-05 | Sanofi | Dérivés de 6,7-dihydro-5h-benzo[7]annulène comme modulateurs de récepteurs d' oestrogènes |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
RS62660B1 (sr) * | 2016-09-27 | 2021-12-31 | Radius Pharmaceuticals Inc | Rad1901 za upotrebu u lečenju karcinoma jajnika |
CN112353796A (zh) | 2016-10-11 | 2021-02-12 | 杜克大学 | Er+乳腺癌的拉索昔芬治疗 |
AU2017362460B2 (en) | 2016-11-17 | 2021-07-22 | Sanofi | Novel substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
EP3565542B1 (fr) * | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Formes polymorphes de rad1901-2hcl |
RU2764724C2 (ru) * | 2017-03-16 | 2022-01-19 | ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. | Комбинированная терапия для лечения рака молочной железы |
EP3434272A1 (fr) * | 2017-07-25 | 2019-01-30 | Sanofi | Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique |
US11179365B2 (en) | 2017-11-16 | 2021-11-23 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and ribociclib |
CN111386113A (zh) | 2017-12-01 | 2020-07-07 | 诺华股份有限公司 | 包含lsz102和阿培利司的药物组合 |
CN112261937B (zh) * | 2018-04-10 | 2023-11-14 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
CN110585429B (zh) * | 2018-06-12 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物***疾病的用途 |
AU2019297421A1 (en) * | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD 1901-2HCL |
AU2019335542A1 (en) | 2018-09-07 | 2021-04-01 | Sanofi | Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-(4-((3s)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxyphenyl)-8,9-dihydro-7H-benzo(7)annulene-2-carboxylate |
CA3120368A1 (fr) * | 2018-11-30 | 2020-06-04 | Radius Pharmaceuticals, Inc. | Elacestrant en combinaison avec de l'abemaciclib chez des femmes atteintes d'un cancer du sein |
JOP20210138A1 (ar) * | 2018-12-06 | 2023-01-30 | Radius Pharmaceuticals Inc | طرق علاج السرطان في نماذج تأوي طفرات esr1 |
MX2021006411A (es) * | 2018-12-06 | 2021-07-21 | Radius Pharmaceuticals Inc | Metodos para el tratamiento del cancer resistente a inhibidores de cinasa 4 y cinasa 6 dependiente de ciclina (cdk4/6). |
KR102341347B1 (ko) * | 2019-11-28 | 2021-12-20 | 의료법인 성광의료재단 | 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법 |
CN115175679A (zh) * | 2020-03-06 | 2022-10-11 | 奥列马制药公司 | 治疗***受体相关疾病的方法 |
CN115551513A (zh) | 2020-05-12 | 2022-12-30 | 基因泰克公司 | 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌 |
CN113662942B (zh) * | 2021-08-19 | 2023-02-07 | 中国人民解放军陆军军医大学第一附属医院 | 药物组合物及其在smo突变性髓母细胞瘤中的应用 |
WO2023064519A1 (fr) | 2021-10-14 | 2023-04-20 | Teva Pharmaceuticals International Gmbh | Formes à l'état solide d'élacestrant et leurs processus de préparation |
WO2024104268A1 (fr) * | 2022-11-15 | 2024-05-23 | 苏州科睿思制药有限公司 | Co-cristal de dichlorhydrate d'élacestrant, son procédé de préparation et son utilisation |
Family Cites Families (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3939346A1 (de) | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
US5589452A (en) | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
US5821225A (en) | 1992-07-14 | 1998-10-13 | Syntex (U.S.A.) Inc. | Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp |
US5977070A (en) | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
DE19517430A1 (de) | 1995-05-12 | 1996-11-14 | Boehringer Mannheim Gmbh | Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode |
IT1285405B1 (it) | 1995-06-06 | 1998-06-03 | Alza Corp | Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto. |
US5723577A (en) | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
US6544949B1 (en) | 1995-07-13 | 2003-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Analogs of parathyroid hormone |
US5969095A (en) | 1995-07-13 | 1999-10-19 | Biomeasure, Inc. | Analogs of parathyroid hormone |
US7410948B2 (en) | 1995-07-13 | 2008-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Analogs of parathyroid hormone |
US5955574A (en) | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
DE19538687A1 (de) | 1995-10-17 | 1997-04-24 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsformen enthaltend Parathormon |
DE19539574A1 (de) | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
TW505654B (en) | 1996-07-30 | 2002-10-11 | Hoffmann La Roche | Synthesis of analogs of PTH and PTHrP |
EP0951551B9 (fr) | 1996-12-23 | 2012-12-26 | Immunex Corporation | Ligand pour l'activateur des recepteurs du nf-kappab, ligand membre de la superfamille de tnf |
US6136784A (en) | 1997-01-08 | 2000-10-24 | Amylin Pharmaceuticals, Inc. | Amylin agonist pharmaceutical compositions containing insulin |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
EP1005359B1 (fr) | 1997-09-09 | 2005-06-15 | F. Hoffmann-La Roche Ag | GUERISON DE FRACTURES AU MOYEN D'ANALOGUES DE PTHrP |
ZA9811127B (en) | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
ATE302041T1 (de) | 1997-12-11 | 2005-09-15 | Alza Corp | Vorrichtung zur erhöhung des transdermalen wirkstoffeflusses |
CN1161164C (zh) | 1997-12-11 | 2004-08-11 | 阿尔扎有限公司 | 用于通过体表导入或提取质剂的装置 |
EP0922467A3 (fr) | 1997-12-12 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Administration de médicaments par ionophorèse |
JP4154017B2 (ja) | 1997-12-30 | 2008-09-24 | 久光製薬株式会社 | イオントフォレーシス装置および薬物ユニット |
US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
SE9801495D0 (sv) | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
US6316410B1 (en) | 1999-09-22 | 2001-11-13 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
WO2001036039A2 (fr) | 1999-11-17 | 2001-05-25 | Novartis Ag | Administration transdermique ionophoretique de peptides |
GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
US20010044431A1 (en) | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
US20050124537A1 (en) | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
EP1325752A3 (fr) | 2000-08-03 | 2003-08-06 | Antares Pharma IPL AG | Composition pour l' administration percutanée et/ou par voie transmucosale de principes actifs assurant des niveaux d'efficacité thérapeutique adéquats |
AU2001282101A1 (en) | 2000-08-23 | 2002-03-04 | Akzo Nobel N.V. | 10-aryl-11-Hbenzo (b)fluorene Derivatives and Analogs for medicinal use |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
DE60138407D1 (de) | 2000-10-26 | 2009-05-28 | Alza Corp | Transdermales arzneistoffverabreichungssytem mit beschichteten mikrovorsprüngen |
MXPA03009603A (es) | 2001-04-20 | 2004-12-06 | Johnson & Johnson | Arreglo de microproyeccion que tiene un agente benefico que contiene un recubrimiento. |
DE60235989D1 (de) | 2001-06-26 | 2010-05-27 | Amgen Fremont Inc | Antikörper gegen opgl |
US6881203B2 (en) | 2001-09-05 | 2005-04-19 | 3M Innovative Properties Company | Microneedle arrays and methods of manufacturing the same |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
RU2314760C2 (ru) | 2001-12-20 | 2008-01-20 | Алза Корпорейшн | Микровыступы, пробивающие кожу, имеющие средство регулирования глубины пробивки |
EP1465619A1 (fr) | 2002-01-14 | 2004-10-13 | Nordic Bioscience A/S | Suppression de la degradation du cartilage a l'aide du recepteur des oestrogenes |
WO2003068805A2 (fr) | 2002-02-14 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Strategies de formulation dans la stabilisation de peptides dans des solvants organiques et a l'etat seche |
CA2496618A1 (fr) | 2002-05-23 | 2003-12-04 | Michael Holick | Utilisation d'analogues peptidiques d'hormone parathyroide pour le traitement de l'atrophie vaginale |
TW200307553A (en) | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
US7799757B2 (en) | 2002-06-13 | 2010-09-21 | Michael Chorev | Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents |
WO2004007520A2 (fr) | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Procedes et compositions visant a prevenir la degradation oxydative de proteines |
EP1523367A1 (fr) | 2002-07-19 | 2005-04-20 | 3M Innovative Properties Company | Dispositifs a microaiguilles et appareils d'application de microaiguilles |
EP1554308A2 (fr) | 2002-10-14 | 2005-07-20 | Novo Nordisk A/S | Variants du peptide glp-2 |
US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
IL152574A (en) | 2002-10-31 | 2009-09-22 | Transpharma Medical Ltd | A system for passing through the skin of dry items or dried medicines |
US8133505B2 (en) | 2002-10-31 | 2012-03-13 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
US7662404B2 (en) | 2002-10-31 | 2010-02-16 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
WO2004060386A1 (fr) | 2002-11-01 | 2004-07-22 | Amgen, Inc. | Modulateurs de recepteurs de l'hormone parathyroide et de la proteine liee a l'hormone parathyroide |
EP1577288B1 (fr) * | 2002-12-26 | 2014-07-23 | Eisai R&D Management Co., Ltd. | Modulateurs selectifs des recepteurs d'oestrogene |
US20060148893A1 (en) | 2003-06-10 | 2006-07-06 | Blanc Jean-Baptiste E | Chemical compounds |
US20060142387A1 (en) | 2003-06-10 | 2006-06-29 | Rodolfo Cadilla | Chemical compounds |
WO2005000309A2 (fr) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Composes chimiques |
KR20060038407A (ko) | 2003-06-30 | 2006-05-03 | 알자 코포레이션 | 비휘발성 반대이온을 포함하는 코팅된 미세돌출부용 제제 |
PL1638468T3 (pl) | 2003-06-30 | 2008-01-31 | Alza Corp | Sposób powlekania mikrowystępów do przekłuwania skóry |
US20050032698A1 (en) | 2003-07-14 | 2005-02-10 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
US7141544B2 (en) | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
AU2004287059A1 (en) | 2003-10-28 | 2005-05-19 | Alza Corporation | Delivery of polymer conjugates of therapeutic peptides and proteins via coated microporjections |
EP1680154B1 (fr) | 2003-10-31 | 2012-01-04 | ALZA Corporation | Applicateur a actionnement automatique pour reseau de micro-protuberances |
EP1682012A4 (fr) | 2003-11-13 | 2008-09-24 | Alza Corp | Composition et appareil d'administration transdermique |
CA2545048A1 (fr) | 2003-11-20 | 2005-06-02 | Warner-Lambert Company Llc | Modulateurs du recepteur androgene |
KR20070011252A (ko) | 2003-11-21 | 2007-01-24 | 알자 코포레이션 | 초음파 보조 경피 백신전달방법 및 시스템 |
IL159273A0 (en) | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
WO2005066194A1 (fr) | 2004-01-07 | 2005-07-21 | Endorecherche, Inc. | Produits pharmaceutiques steroidiens diriges sur l'helice 12 |
IL160033A0 (en) | 2004-01-25 | 2004-06-20 | Transpharma Medical Ltd | Transdermal delivery system for polynucleotides |
TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
CN1942187A (zh) | 2004-04-08 | 2007-04-04 | 默克公司 | 作为雄激素受体调节剂的17β-乙酰胺-4-氮杂甾体化合物 |
RU2006143544A (ru) | 2004-05-10 | 2008-06-20 | Нэстек Фармасьютикал Кампани Инк. (Us) | Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона |
CA2565544A1 (fr) | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Derives de benzonitrile destines au traitement de la fragilite musculo-squelettique |
MXPA06013168A (es) | 2004-05-13 | 2007-05-15 | Johnson & Johnson | Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea. |
EP1765406A4 (fr) | 2004-05-21 | 2012-11-28 | Mediplex Corp | Delivrance d'agents permettant d'ameliorer l'absorption mucosale d'agents therapeutiques |
US7906137B2 (en) | 2004-05-21 | 2011-03-15 | Mediplex Corporation, Korea | Delivery agents for enhancing mucosal absorption of therapeutic agents |
US20090069226A1 (en) | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
JP2008518968A (ja) | 2004-10-29 | 2008-06-05 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体モジュレーターとしてのn−(ピリジン−3−イル)−2−フェニルブタンアミド |
US8057842B2 (en) | 2004-11-18 | 2011-11-15 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
EP1827564B1 (fr) | 2004-11-18 | 2015-07-29 | 3M Innovative Properties Company | Procede de masquage pour le revetement d'un jeu de micro-aiguilles |
WO2006054299A2 (fr) | 2004-11-18 | 2006-05-26 | Transpharma Medical Ltd. | Production de micro-canaux associes et iontophorese pour une administration transdermique d'agents pharmaceutiques |
JP2008528509A (ja) | 2005-01-21 | 2008-07-31 | アルザ コーポレイション | 少なくとも1つの対イオンを含む、向上した安定性でマイクロニードルをコーティングするための治療用ペプチド製剤 |
WO2006113552A2 (fr) | 2005-04-15 | 2006-10-26 | Smithkline Beecham Corporation | Cyanoarylamines |
KR100700869B1 (ko) | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물 |
US20090170907A1 (en) | 2005-06-06 | 2009-07-02 | Smithkline Beecham Corporation | Chemical Compounds |
WO2007005887A2 (fr) | 2005-07-01 | 2007-01-11 | Ligand Pharmaceuticals Incorporated | Composes de modulation des recepteur des androgenes et methodes associees |
US20070021216A1 (en) | 2005-07-19 | 2007-01-25 | Sony Ericsson Mobile Communications Ab | Seamless gaming method and apparatus |
JP2008303145A (ja) | 2005-09-22 | 2008-12-18 | Takeda Chem Ind Ltd | Grk阻害剤からなる強心薬 |
EP1948139A4 (fr) | 2005-11-18 | 2012-04-04 | 3M Innovative Properties Co | Compositions pouvant être revêtues, revêtements dérivés de celles-ci et micro-réseaux comprenant de tels revêtements |
ES2551305T3 (es) | 2005-12-28 | 2015-11-17 | Alza Corporation | Formulaciones terapéuticas estables |
CN101466393A (zh) | 2006-03-15 | 2009-06-24 | 阿尔扎公司 | 用于经皮递送甲状旁腺激素药剂以治疗骨质减少的方法 |
US9119945B2 (en) | 2006-04-20 | 2015-09-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
US8048383B2 (en) | 2006-04-20 | 2011-11-01 | Velocys, Inc. | Process for treating and/or forming a non-Newtonian fluid using microchannel process technology |
CA2648939C (fr) | 2006-04-20 | 2014-07-08 | Amgen Inc. | Formules d'emulsions stables |
CN101085743B (zh) | 2006-06-06 | 2012-02-15 | 浙江大德药业集团有限公司 | 含氟烷氧基康普立停衍生物及制法和用途 |
EP2037905B1 (fr) | 2006-06-23 | 2013-05-01 | Radius Health, Inc. | Traitement de symptômes vasomoteurs par des modulateurs des récepteurs d' strogène sélectifs |
EP2038252B1 (fr) | 2006-07-12 | 2016-11-02 | University of Tennessee Research Foundation | Acylanilides substitués et procédés d'utilisation de ceux-ci |
CN103251579B (zh) | 2006-08-24 | 2016-12-28 | 田纳西大学研究基金会 | 取代的n-酰基苯胺及其使用方法 |
AR062522A1 (es) | 2006-08-25 | 2008-11-12 | Ares Trading Sa | Tratamiento de desordenes en cartilagos |
CN1927815A (zh) | 2006-09-25 | 2007-03-14 | 天津理工大学 | 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途 |
US7803770B2 (en) | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
PT2957278T (pt) | 2006-10-03 | 2017-08-23 | Ipsen Pharma Sas | Uma composição estável compreendendo pthrp e utilizações da mesma |
WO2008044033A1 (fr) | 2006-10-11 | 2008-04-17 | Astrazeneca Ab | Dérivés d'amide |
JP5241517B2 (ja) | 2007-02-06 | 2013-07-17 | 久光製薬株式会社 | アレルギー診断用マイクロニードルデバイス |
WO2008121602A1 (fr) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Composés chimiques |
WO2008124000A2 (fr) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Dérivés de thiazole utilisés comme composés modulateurs de récepteurs d'androgènes |
WO2008130587A2 (fr) | 2007-04-16 | 2008-10-30 | Corium International, Inc. | Réseaux de micro-aiguilles coulées dans un solvant contenant un actif |
GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
EP2155905A1 (fr) * | 2007-05-31 | 2010-02-24 | Dako Denmark A/S | Procédés d'utilisation des changements du nombre de copies d'esr dans les traitements et les pronostics du cancer du sein |
WO2008156613A1 (fr) | 2007-06-12 | 2008-12-24 | Schering Corporation | Biomarqueur de l'histone h2ax (hh2ax) pour une sensibilité à fti |
US8450481B2 (en) | 2007-06-14 | 2013-05-28 | The Regents Of The University Of California | Compounds for inhibiting protein aggregation, and methods for making and using them |
US20120150023A1 (en) | 2007-08-06 | 2012-06-14 | Kaspar Roger L | Microneedle arrays for active agent delivery |
CN101808588B (zh) | 2007-09-28 | 2012-12-19 | 贝尔法斯特女王大学 | 递送装置及方法 |
US20090117158A1 (en) | 2007-10-23 | 2009-05-07 | Mahmoud Ameri | Transdermal sustained release drug delivery |
EP2052736A1 (fr) | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Formulations d'hormones parathyroïdiennes et leurs utilisations |
CN101795680A (zh) | 2007-11-16 | 2010-08-04 | 波苏蛋白试剂公司 | 稳定蛋白质的辅剂 |
WO2009133861A1 (fr) | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | Composé amine cyclique |
WO2009137104A1 (fr) * | 2008-05-09 | 2009-11-12 | Radius Health, Inc. | Traitement combiné contre le cancer du sein comprenant un agent antioestrogène |
WO2010022176A1 (fr) | 2008-08-19 | 2010-02-25 | Ferring International Center S.A. | Méthodes pour traiter des maladies du squelette |
CA2738715C (fr) | 2008-10-15 | 2013-07-16 | Intarcia Therapeutics, Inc. | Particules medicamenteuses hautement concentrees, formes pharmaceutiques, suspensions et leurs utilisations |
US8329649B2 (en) | 2008-11-04 | 2012-12-11 | Aska Pharmaceutical Co., Ltd. | Aqueous composition containing follicle-stimulating hormone and histidine |
EP2355887B1 (fr) | 2008-11-18 | 2017-08-02 | 3M Innovative Properties Company | Ensemble de microaiguilles creuses |
US20110288485A1 (en) | 2008-12-26 | 2011-11-24 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle device |
US20100203014A1 (en) | 2009-02-04 | 2010-08-12 | Aegis Therapeutics Llc | Zwitterionic buffered acidic peptide and protein formulations |
US20100226966A1 (en) | 2009-03-03 | 2010-09-09 | Daddona Peter E | Method for transdermal controlled release drug delivery |
WO2010118287A1 (fr) | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Modulateurs sélectifs du récepteur aux androgènes |
CA2759850C (fr) | 2009-04-24 | 2019-10-22 | Corium International, Inc. | Procedes destines a la fabrication de reseaux de microsaillie |
CN102497909B (zh) | 2009-07-31 | 2014-10-29 | 3M创新有限公司 | 中空微针阵列 |
CA2779577A1 (fr) | 2009-11-02 | 2011-05-05 | Therapeomic Ag | Formulations de proteine stabilisees et utilisation correspondante |
US20110172609A1 (en) | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Microneedle component assembly for drug delivery device |
CN101912600B (zh) | 2010-01-11 | 2014-01-29 | 杨国汉 | 改善胰岛素在溶液中稳定性的方法 |
IE20100174A1 (en) | 2010-03-25 | 2012-02-29 | Trinity College Dublin | Transdermal administration of peptides |
AU2011248108B2 (en) | 2010-05-04 | 2016-05-26 | Corium Pharma Solutions, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
US9693950B2 (en) | 2010-05-28 | 2017-07-04 | 3M Innovative Properties Company | Aqueous formulations for coating microneedle arrays |
KR20190042762A (ko) * | 2010-06-16 | 2019-04-24 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
WO2012075375A1 (fr) | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Administration d'hormones parathyroïdiennes par des systèmes de micro-injection |
WO2012119004A2 (fr) | 2011-03-01 | 2012-09-07 | Sloan-Kettering Institute For Cancer Research | Analogues de l'hormone parathyroïdienne, compositions et utilisations connexes |
EP3332799A1 (fr) | 2011-04-22 | 2018-06-13 | Radius Health, Inc. | Procédé d'administration de médicaments pour pth, pthrp et peptides associés |
US9623087B2 (en) | 2011-11-30 | 2017-04-18 | 3M Innovative Properties Company | Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same |
GB201217439D0 (en) | 2012-09-28 | 2012-11-14 | Topotarget As | Combination therapy |
WO2014203129A1 (fr) * | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinaisons de composés benzopyrane, leurs compositions et utilisations |
WO2014205136A1 (fr) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Modulateurs azétidine des récepteurs d'œstrogènes et leurs utilisations |
CN104436194B (zh) | 2013-09-18 | 2018-03-30 | 北京大学 | 具有协同增效作用的抗癌组合物 |
WO2015113062A1 (fr) * | 2014-01-27 | 2015-07-30 | Dna-Seq, Inc. | Méthodes et systèmes de détermination d'un schéma thérapeutique efficace et de découverte de médicaments |
CA2940576A1 (fr) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Combinaisons therapeutiques avec des modulateurs du recepteur des strogenes |
DK3122426T3 (da) * | 2014-03-28 | 2023-04-03 | Univ Duke | Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
WO2015160986A2 (fr) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Polythérapies |
JP6807841B2 (ja) | 2014-12-18 | 2021-01-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーター及びその使用 |
AR104068A1 (es) * | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
EP4039253A1 (fr) * | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Procédés de traitement du cancer |
-
2016
- 2016-04-29 EP EP22155988.3A patent/EP4039253A1/fr active Pending
- 2016-04-29 CN CN202110933929.XA patent/CN113750091A/zh active Pending
- 2016-04-29 JP JP2018509731A patent/JP6926065B2/ja active Active
- 2016-04-29 BR BR112017023233A patent/BR112017023233A2/pt not_active Application Discontinuation
- 2016-04-29 KR KR1020177034606A patent/KR20180043202A/ko active IP Right Grant
- 2016-04-29 IL IL255261A patent/IL255261B2/en unknown
- 2016-04-29 RU RU2017140675A patent/RU2747228C2/ru active
- 2016-04-29 SG SG10202104177VA patent/SG10202104177VA/en unknown
- 2016-04-29 EP EP16787289.4A patent/EP3288382A4/fr active Pending
- 2016-04-29 MX MX2017013794A patent/MX2017013794A/es unknown
- 2016-04-29 AU AU2016256470A patent/AU2016256470B2/en active Active
- 2016-04-29 BR BR112017023269A patent/BR112017023269A2/pt not_active Application Discontinuation
- 2016-04-29 BR BR112017023228A patent/BR112017023228A2/pt not_active Application Discontinuation
- 2016-04-29 AU AU2016256471A patent/AU2016256471B2/en active Active
- 2016-04-29 KR KR1020177034603A patent/KR20180011780A/ko active IP Right Grant
- 2016-04-29 KR KR1020177034608A patent/KR20180042155A/ko active IP Right Grant
- 2016-04-29 CA CA2984357A patent/CA2984357A1/fr active Pending
- 2016-04-29 AU AU2016256469A patent/AU2016256469B2/en active Active
- 2016-04-29 EP EP16787291.0A patent/EP3288383A4/fr active Pending
- 2016-04-29 SG SG11201708861VA patent/SG11201708861VA/en unknown
- 2016-04-29 CN CN202110579478.4A patent/CN113288887A/zh active Pending
- 2016-04-29 MX MX2017013801A patent/MX2017013801A/es unknown
- 2016-04-29 IL IL297369A patent/IL297369B1/en unknown
- 2016-04-29 JP JP2017556627A patent/JP7019422B2/ja active Active
- 2016-04-29 SG SG11201708858WA patent/SG11201708858WA/en unknown
- 2016-04-29 CA CA2984200A patent/CA2984200C/fr active Active
- 2016-04-29 CA CA2984195A patent/CA2984195C/fr active Active
- 2016-04-29 MX MX2021005561A patent/MX2021005561A/es unknown
- 2016-04-29 MX MX2017013802A patent/MX2017013802A/es unknown
- 2016-04-29 CN CN201680039059.9A patent/CN108024541B/zh active Active
- 2016-04-29 IL IL255189A patent/IL255189B2/en unknown
- 2016-04-29 EP EP16787290.2A patent/EP3294065A4/fr active Pending
- 2016-04-29 WO PCT/US2016/030317 patent/WO2016176665A1/fr active Application Filing
- 2016-04-29 RU RU2017140674A patent/RU2737496C2/ru active
- 2016-04-29 RU RU2017140676A patent/RU2745678C2/ru active
- 2016-04-29 WO PCT/US2016/030316 patent/WO2016176664A1/fr active Application Filing
- 2016-04-29 SG SG11201708860SA patent/SG11201708860SA/en unknown
- 2016-04-29 CN CN201680038908.9A patent/CN108135177B/zh active Active
- 2016-04-29 CN CN201680038907.4A patent/CN108024540B/zh active Active
- 2016-04-29 WO PCT/US2016/030321 patent/WO2016176666A1/fr active Application Filing
- 2016-04-29 IL IL307981A patent/IL307981A/en unknown
- 2016-04-29 IL IL307983A patent/IL307983A/en unknown
- 2016-04-29 IL IL255148A patent/IL255148B2/en unknown
- 2016-04-29 IL IL310069A patent/IL310069A/en unknown
- 2016-04-29 JP JP2018509732A patent/JP6926066B2/ja active Active
-
2017
- 2017-10-26 US US15/794,910 patent/US20180214393A1/en not_active Abandoned
- 2017-10-26 US US15/794,774 patent/US20180153828A1/en not_active Abandoned
- 2017-10-26 MX MX2021004881A patent/MX2021004881A/es unknown
- 2017-10-26 MX MX2021003389A patent/MX2021003389A/es unknown
- 2017-10-26 US US15/794,861 patent/US20180169101A1/en not_active Abandoned
-
2018
- 2018-08-24 HK HK18110956.1A patent/HK1251408A1/zh unknown
- 2018-08-24 HK HK18110955.2A patent/HK1251407A1/zh unknown
- 2018-08-24 HK HK18110957.0A patent/HK1251409A1/zh unknown
-
2019
- 2019-08-20 US US16/545,859 patent/US20200046655A1/en not_active Abandoned
- 2019-09-24 US US16/580,914 patent/US11413258B2/en active Active
-
2020
- 2020-08-04 US US16/985,021 patent/US11819480B2/en active Active
-
2021
- 2021-03-25 JP JP2021052305A patent/JP7146992B2/ja active Active
- 2021-04-23 JP JP2021073337A patent/JP7262508B2/ja active Active
- 2021-10-25 US US17/510,050 patent/US20220110890A1/en active Granted
-
2022
- 2022-06-29 US US17/852,673 patent/US20220339126A1/en active Pending
- 2022-09-21 JP JP2022150560A patent/JP2022172039A/ja active Pending
-
2023
- 2023-01-25 JP JP2023009598A patent/JP2023052631A/ja active Pending
- 2023-09-12 US US18/367,103 patent/US20240099996A1/en active Pending
- 2023-11-16 US US18/511,036 patent/US20240091177A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017023269A2 (pt) | métodos para tratamento de câncer | |
MX2019005465A (es) | Metodo de tratamiento de un tumor inmunoterapeutico. | |
PH12016502179A1 (en) | Inhibitors of lysine specific demethylase-1 | |
BR112015019995A2 (pt) | Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer | |
MY190034A (en) | Method of treating cancer associated with a ras mutation | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
PH12016501790B1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
BR112014031421A2 (pt) | composições para tratamento de câncer e métodos para produção das mesmas | |
TW201613901A (en) | New compounds | |
BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
PH12016501788A1 (en) | Pharmaceutical compositions of therapeutically active compounds | |
EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
TW201613882A (en) | Histone demethylase inhibitors | |
TN2017000032A1 (en) | Protein kinase c inhibitors and methods of their use | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
MY199091A (en) | Therapeutic compounds | |
PH12019500135A1 (en) | Methods of treating prostate cancer | |
PH12016000355B1 (en) | Use of xanthophylls for the treatment of cancers | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
IN2013MU03118A (fr) | ||
MX2017013669A (es) | Composiciones para el tramiento del cancer. | |
EA201592012A1 (ru) | Применение флагеллина для улучшенной химиотерапии | |
EA201990411A1 (ru) | Способы лечения рака предстательной железы | |
EA201492019A1 (ru) | Способы лечения рака с помощью липопептидов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B25G | Requested change of headquarter approved |
Owner name: RADIUS PHARMACEUTICALS, INC. (US) |
|
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 57/00 , A01N 57/10 Ipc: A61K 31/137 (2006.01), A61K 31/138 (2006.01), A61K |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |